{"success":true,"data":{"pressRelease":{"id":"138464","rtpr_id":"nPn5jJ0B9a-20260908","ticker":"ZBH","exchange":"NYSE","all_tickers":["ZBH"],"title":"Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation","author":"PR Newswire","published_at":"2026-09-08T20:30:00.438Z","article_body":"Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation\n\nPR Newswire\n\nWARSAW, Ind., Sept. 8, 2026\n\nGary Campbell promoted to President, Americas\nBrian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery\n\nBradley Kessler promoted to President, Americas – Robotics, Technology and\nData\n\nWARSAW, Ind., Sept. 8, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.\n(NYSE and SIX: ZBH), a global medical technology leader, today announced\nleadership appointments designed to streamline its Americas and Global\nBusiness Group organizations for greater focus and agility.\n\nEffective October 1, Gary Campbell will be promoted to President, Americas,\nand Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro\nand Biosurgery. The company also announced the promotion of Bradley Kessler to\nPresident, Americas – Robotics, Technology and Data. Campbell, Hatcher and\nKessler will report directly to Ivan Tornos, Chairman, President and CEO of\nZimmer Biomet.\n\n\"We talk often about our People and Culture strategic imperative to have the\nright talent, in the right roles, at the right times,\" said Tornos. \"These\nwell-deserved promotions do exactly that, while helping to accelerate our U.S.\ngo-to-market transformation and sharpen ownership of our most important\ncommercial priorities. Gary, Brian and Brad are seasoned operators and proven\nZimmer Biomet leaders with deep experience in the businesses and markets they\nwill now lead. Their promotions reinforce my strong confidence in both our\n2026 outlook and our growth potential in 2027 and beyond.\"\n\nAs part of this restructuring, Kevin Thornal, Group President, Global\nBusinesses and the Americas, will leave the company on September 30, 2026,\nfollowing a transition period.\n\nTornos added, \"On behalf of the entire Zimmer Biomet team, I want to thank\nKevin for his leadership and contributions to our company. We wish him all the\nbest in his next chapter.\"\n\n2026 Outlook\nZimmer Biomet also announced today that the Company is reiterating its\nfull-year 2026 financial outlook provided on August 5, 2026.\n\nAbout Gary Campbell\nAs President, Americas, Campbell will be responsible for commercial strategy\nand execution across the United States, Canada and Latin America. He will\ncontinue to lead the evolution of the company's U.S. go-to-market model,\nbuilding a specialized and dedicated organization designed to increase\nproductivity and accelerate growth.\n\nCampbell has served as Zimmer Biomet's vice president and general manager,\nOrthopedics – North America since September 2024. Since joining the company\nin 2019, Campbell has held multiple commercial leadership roles of increasing\nresponsibility. Previously, Campbell served in several sales and marketing\nroles at Enovis. He holds a bachelor's degree from Texas State University.\n\nAbout Brian Hatcher\nAs President, Recon, S.E.T., CMFT, Neuro and Biosurgery, Hatcher will lead\nglobal portfolio strategy and execution across most of the company's\nbusinesses, expanding his current remit to include Global Knees and Hips. He\nwill continue to play an integral role in the company's innovation and\ndiversification strategy, including delivering organic and inorganic\nopportunities in higher growth markets. Lou Galrao, President of\nReconstruction (Knees and Hips), will report to Hatcher.\n\nDuring his 16-year career with Zimmer Biomet, Hatcher has held multiple roles\nin research, marketing, general management and business leadership. He was\nnamed to his first Global President role in 2021 and currently serves as\nZimmer Biomet's President of S.E.T. and CMFT. Hatcher began his medical\ntechnology career with roles at OrbusNeich and later Medtronic. He holds a\nbachelor's degree in chemistry and a Ph.D. in biomedical engineering, both\nfrom the University of Florida.\n\nAbout Brad Kessler\nAs President, Americas – Robotics, Technology and Data, Kessler will be\nresponsible for driving commercial strategy, growth and adoption of the\ncompany's broad portfolio of robotics, digital and technology solutions in the\nAmericas, as well as its global service and capital solutions contracting\nbusiness. Under Kessler's leadership, the company will accelerate the\nexpansion of its specialized robotics salesforce in advance of the highly\nanticipated launch of the Monogram next-generation orthopedic robot, which is\nexpected in 2027.\n\nKessler brings to the role more than two decades of commercial experience in\northopedics. Currently vice president and general manager, Robotics,\nTechnology and Data Solutions, Kessler has held multiple commercial leadership\nroles of increasing responsibility since he joined Zimmer Biomet in 2015.\nPrior to joining Zimmer Biomet, Kessler spent nearly 10 years in sales at\nStryker. He holds a bachelor's degree from Texas A&M University and an\nExecutive MBA from the Cox School of Business at Southern Methodist\nUniversity.\n\nAbout Zimmer Biomet\nZimmer Biomet is a global medical technology leader with a comprehensive\nportfolio designed to maximize mobility and improve health. We seamlessly\ntransform the patient experience through our innovative products and suite of\nintegrated digital and robotic technologies that leverage data, data analytics\nand artificial intelligence.\n\nWith 90+ years of trusted leadership and proven expertise, Zimmer Biomet is\npositioned to deliver the highest quality solutions to patients and\nproviders. Our legacy continues to come to life today through our progressive\nculture of evolution and innovation.\n\nFor more information about our product portfolio, our operations in 25+\ncountries and sales in 100+ countries or about joining our team, visit\nwww.zimmerbiomet.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4769401-1&h=3274195791&u=http%3A%2F%2Fwww.zimmerbiomet.com%2F&a=www.zimmerbiomet.com)\n or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4769401-1&h=2866201997&u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzimmerbiomet&a=www.linkedin.com%2Fcompany%2Fzimmerbiomet)\n or X at www.x.com/zimmerbiomet\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4769401-1&h=1150674684&u=http%3A%2F%2Fwww.x.com%2Fzimmerbiomet&a=www.x.com%2Fzimmerbiomet)\n.\n\nCautionary Note Regarding Forward-Looking Statements\nThis news release contains forward-looking statements within the meaning of\nthe safe harbor provisions of the Private Securities Litigation Reform Act of\n1995. Forward-looking statements include, but are not limited to, statements\nconcerning Zimmer Biomet's expectations, plans, outlook, prospects, and\nproduct and service offerings, including new product launches and potential\nclinical successes. Such statements are based upon the current beliefs and\nexpectations of management and are subject to significant risks, uncertainties\nand changes in circumstances that could cause actual outcomes and results to\ndiffer materially. For a list and description of some of such risks and\nuncertainties, see Zimmer Biomet's periodic reports filed with the U.S.\nSecurities and Exchange Commission (\"SEC\"). These factors should not be\nconstrued as exhaustive and should be read in conjunction with the other\ncautionary statements that are included in Zimmer Biomet's filings with the\nSEC. Forward-looking statements speak only as of the date they are made, and\nZimmer Biomet disclaims any intention or obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise. Readers of this news release are cautioned not to rely on\nthese forward-looking statements, since there can be no assurance that these\nforward-looking statements will prove to be accurate. This cautionary\nstatement is applicable to all forward-looking statements contained in this\nnews release.\n Contacts:                                                                      Investors\n\nMedia\nDavid DeMartino\n\nTroy Kirkpatrick\n646-531-6115\n\n614-284-1926\ndavid.demartino@zimmerbiomet.com (mailto:david.demartino@zimmerbiomet.com)\n\ntroy.kirkpatrick@zimmerbiomet.com (mailto:troy.kirkpatrick@zimmerbiomet.com)\nZach Weiner\n\n908-591-6955\n\nKirsten Fallon\nzach.weiner@zimmerbiomet.com (mailto:zach.weiner@zimmerbiomet.com)\n\n781-779-5561\n\nkirsten.fallon@zimmerbiomet.com (mailto:kirsten.fallon@zimmerbiomet.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-americas-leadership-promotions-to-accelerate-commercial-transformation-302872765.html\n(https://www.prnewswire.com/news-releases/zimmer-biomet-announces-americas-leadership-promotions-to-accelerate-commercial-transformation-302872765.html)\n\nSOURCE Zimmer Biomet Holdings, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS118145/Zimmer-Biomet-Holdings-Logo.jpg?id=OA2936136\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5jJ0B9a-20260908","title":"Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation","author":"PR Newswire","ticker":"ZBH","created":"2026-09-08T20:30:00.438Z","tickers":["ZBH"],"exchange":"NYSE","article_body":"Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation\n\nPR Newswire\n\nWARSAW, Ind., Sept. 8, 2026\n\nGary Campbell promoted to President, Americas\nBrian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery\n\nBradley Kessler promoted to President, Americas – Robotics, Technology and\nData\n\nWARSAW, Ind., Sept. 8, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.\n(NYSE and SIX: ZBH), a global medical technology leader, today announced\nleadership appointments designed to streamline its Americas and Global\nBusiness Group organizations for greater focus and agility.\n\nEffective October 1, Gary Campbell will be promoted to President, Americas,\nand Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro\nand Biosurgery. The company also announced the promotion of Bradley Kessler to\nPresident, Americas – Robotics, Technology and Data. Campbell, Hatcher and\nKessler will report directly to Ivan Tornos, Chairman, President and CEO of\nZimmer Biomet.\n\n\"We talk often about our People and Culture strategic imperative to have the\nright talent, in the right roles, at the right times,\" said Tornos. \"These\nwell-deserved promotions do exactly that, while helping to accelerate our U.S.\ngo-to-market transformation and sharpen ownership of our most important\ncommercial priorities. Gary, Brian and Brad are seasoned operators and proven\nZimmer Biomet leaders with deep experience in the businesses and markets they\nwill now lead. Their promotions reinforce my strong confidence in both our\n2026 outlook and our growth potential in 2027 and beyond.\"\n\nAs part of this restructuring, Kevin Thornal, Group President, Global\nBusinesses and the Americas, will leave the company on September 30, 2026,\nfollowing a transition period.\n\nTornos added, \"On behalf of the entire Zimmer Biomet team, I want to thank\nKevin for his leadership and contributions to our company. We wish him all the\nbest in his next chapter.\"\n\n2026 Outlook\nZimmer Biomet also announced today that the Company is reiterating its\nfull-year 2026 financial outlook provided on August 5, 2026.\n\nAbout Gary Campbell\nAs President, Americas, Campbell will be responsible for commercial strategy\nand execution across the United States, Canada and Latin America. He will\ncontinue to lead the evolution of the company's U.S. go-to-market model,\nbuilding a specialized and dedicated organization designed to increase\nproductivity and accelerate growth.\n\nCampbell has served as Zimmer Biomet's vice president and general manager,\nOrthopedics – North America since September 2024. Since joining the company\nin 2019, Campbell has held multiple commercial leadership roles of increasing\nresponsibility. Previously, Campbell served in several sales and marketing\nroles at Enovis. He holds a bachelor's degree from Texas State University.\n\nAbout Brian Hatcher\nAs President, Recon, S.E.T., CMFT, Neuro and Biosurgery, Hatcher will lead\nglobal portfolio strategy and execution across most of the company's\nbusinesses, expanding his current remit to include Global Knees and Hips. He\nwill continue to play an integral role in the company's innovation and\ndiversification strategy, including delivering organic and inorganic\nopportunities in higher growth markets. Lou Galrao, President of\nReconstruction (Knees and Hips), will report to Hatcher.\n\nDuring his 16-year career with Zimmer Biomet, Hatcher has held multiple roles\nin research, marketing, general management and business leadership. He was\nnamed to his first Global President role in 2021 and currently serves as\nZimmer Biomet's President of S.E.T. and CMFT. Hatcher began his medical\ntechnology career with roles at OrbusNeich and later Medtronic. He holds a\nbachelor's degree in chemistry and a Ph.D. in biomedical engineering, both\nfrom the University of Florida.\n\nAbout Brad Kessler\nAs President, Americas – Robotics, Technology and Data, Kessler will be\nresponsible for driving commercial strategy, growth and adoption of the\ncompany's broad portfolio of robotics, digital and technology solutions in the\nAmericas, as well as its global service and capital solutions contracting\nbusiness. Under Kessler's leadership, the company will accelerate the\nexpansion of its specialized robotics salesforce in advance of the highly\nanticipated launch of the Monogram next-generation orthopedic robot, which is\nexpected in 2027.\n\nKessler brings to the role more than two decades of commercial experience in\northopedics. Currently vice president and general manager, Robotics,\nTechnology and Data Solutions, Kessler has held multiple commercial leadership\nroles of increasing responsibility since he joined Zimmer Biomet in 2015.\nPrior to joining Zimmer Biomet, Kessler spent nearly 10 years in sales at\nStryker. He holds a bachelor's degree from Texas A&M University and an\nExecutive MBA from the Cox School of Business at Southern Methodist\nUniversity.\n\nAbout Zimmer Biomet\nZimmer Biomet is a global medical technology leader with a comprehensive\nportfolio designed to maximize mobility and improve health. We seamlessly\ntransform the patient experience through our innovative products and suite of\nintegrated digital and robotic technologies that leverage data, data analytics\nand artificial intelligence.\n\nWith 90+ years of trusted leadership and proven expertise, Zimmer Biomet is\npositioned to deliver the highest quality solutions to patients and\nproviders. Our legacy continues to come to life today through our progressive\nculture of evolution and innovation.\n\nFor more information about our product portfolio, our operations in 25+\ncountries and sales in 100+ countries or about joining our team, visit\nwww.zimmerbiomet.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4769401-1&h=3274195791&u=http%3A%2F%2Fwww.zimmerbiomet.com%2F&a=www.zimmerbiomet.com)\n or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4769401-1&h=2866201997&u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzimmerbiomet&a=www.linkedin.com%2Fcompany%2Fzimmerbiomet)\n or X at www.x.com/zimmerbiomet\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4769401-1&h=1150674684&u=http%3A%2F%2Fwww.x.com%2Fzimmerbiomet&a=www.x.com%2Fzimmerbiomet)\n.\n\nCautionary Note Regarding Forward-Looking Statements\nThis news release contains forward-looking statements within the meaning of\nthe safe harbor provisions of the Private Securities Litigation Reform Act of\n1995. Forward-looking statements include, but are not limited to, statements\nconcerning Zimmer Biomet's expectations, plans, outlook, prospects, and\nproduct and service offerings, including new product launches and potential\nclinical successes. Such statements are based upon the current beliefs and\nexpectations of management and are subject to significant risks, uncertainties\nand changes in circumstances that could cause actual outcomes and results to\ndiffer materially. For a list and description of some of such risks and\nuncertainties, see Zimmer Biomet's periodic reports filed with the U.S.\nSecurities and Exchange Commission (\"SEC\"). These factors should not be\nconstrued as exhaustive and should be read in conjunction with the other\ncautionary statements that are included in Zimmer Biomet's filings with the\nSEC. Forward-looking statements speak only as of the date they are made, and\nZimmer Biomet disclaims any intention or obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise. Readers of this news release are cautioned not to rely on\nthese forward-looking statements, since there can be no assurance that these\nforward-looking statements will prove to be accurate. This cautionary\nstatement is applicable to all forward-looking statements contained in this\nnews release.\n Contacts:                                                                      Investors\n\nMedia\nDavid DeMartino\n\nTroy Kirkpatrick\n646-531-6115\n\n614-284-1926\ndavid.demartino@zimmerbiomet.com (mailto:david.demartino@zimmerbiomet.com)\n\ntroy.kirkpatrick@zimmerbiomet.com (mailto:troy.kirkpatrick@zimmerbiomet.com)\nZach Weiner\n\n908-591-6955\n\nKirsten Fallon\nzach.weiner@zimmerbiomet.com (mailto:zach.weiner@zimmerbiomet.com)\n\n781-779-5561\n\nkirsten.fallon@zimmerbiomet.com (mailto:kirsten.fallon@zimmerbiomet.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-americas-leadership-promotions-to-accelerate-commercial-transformation-302872765.html\n(https://www.prnewswire.com/news-releases/zimmer-biomet-announces-americas-leadership-promotions-to-accelerate-commercial-transformation-302872765.html)\n\nSOURCE Zimmer Biomet Holdings, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS118145/Zimmer-Biomet-Holdings-Logo.jpg?id=OA2936136\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-08T20:30:00.488345329Z","server_sent_at_ms":1788899400488},"received_at":"2026-09-08T20:30:00.543Z","source_url":"https://www.prnewswire.com/news-releases/zimmer-biomet-announces-americas-leadership-promotions-to-accelerate-commercial-transformation-302872765.html"},"analysis":{"id":"127316","press_release_id":"138464","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Zimmer Biomet announced three executive promotions effective October 1, 2026, to streamline its Americas and Global Business Group organizations.\n\nGary Campbell was promoted to President, Americas; Brian Hatcher to President of Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data.\n\nThe company also noted that Group President Kevin Thornal will leave the company on September 30, 2026, following a transition period.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Leadership reshuffle to sharpen commercial focus and accelerate go-to-market transformation."},"keyFigures":{"customDimensions":{"effective_date":"October 1, 2026"}},"quotedText":"These well-deserved promotions do exactly that, while helping to accelerate our U.S. go-to-market transformation and sharpen ownership of our most important commercial priorities.","namedEntities":{"people":[{"name":"Gary Campbell","role":"President, Americas"},{"name":"Brian Hatcher","role":"President, Recon, S.E.T., CMFT, Neuro and Biosurgery"},{"name":"Bradley Kessler","role":"President, Americas – Robotics, Technology and Data"},{"name":"Ivan Tornos","role":"Chairman, President and CEO"},{"name":"Kevin Thornal","role":"Group President, Global Businesses and the Americas (departing)"}],"products":["Monogram next-generation orthopedic robot"],"companies":[{"name":"Zimmer Biomet Holdings, Inc.","ticker":"ZBH"},{"name":"Enovis","relationship":"previous employer"},{"name":"OrbusNeich","relationship":"previous employer"},{"name":"Medtronic","relationship":"previous employer"},{"name":"Stryker","relationship":"previous employer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Leadership promotions are positive for organizational focus and agility, but they are routine internal changes rather than a material financial or strategic event."},"tickerRelevance":{"others":[],"primary":"ZBH"},"globalImportance":25,"audienceRelevance":40,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"leadership_change","sectorWeight":"Health Care","householdBrandBoost":0}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Zimmer Biomet announced three executive promotions effective October 1, 2026, to streamline its Americas and Global Business Group organizations.\n\nGary Campbell was promoted to President, Americas; Brian Hatcher to President of Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data.\n\nThe company also noted that Group President Kevin Thornal will leave the company on September 30, 2026, following a transition period.","key_figures":{"customDimensions":{"effective_date":"October 1, 2026"}},"named_entities":{"people":[{"name":"Gary Campbell","role":"President, Americas"},{"name":"Brian Hatcher","role":"President, Recon, S.E.T., CMFT, Neuro and Biosurgery"},{"name":"Bradley Kessler","role":"President, Americas – Robotics, Technology and Data"},{"name":"Ivan Tornos","role":"Chairman, President and CEO"},{"name":"Kevin Thornal","role":"Group President, Global Businesses and the Americas (departing)"}],"products":["Monogram next-generation orthopedic robot"],"companies":[{"name":"Zimmer Biomet Holdings, Inc.","ticker":"ZBH"},{"name":"Enovis","relationship":"previous employer"},{"name":"OrbusNeich","relationship":"previous employer"},{"name":"Medtronic","relationship":"previous employer"},{"name":"Stryker","relationship":"previous employer"}],"dollarAmounts":[]},"model_name":"glm-4.7-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-08T20:39:26.429Z","global_importance":25,"audience_relevance":40,"importance_components":{"tickerTier":"large-cap","eventGravity":"leadership_change","sectorWeight":"Health Care","householdBrandBoost":0}},"durationMs":54875,"modelName":"glm-4.7-flashx"}}